Retatrutide is currently classified as an Investigational New Drug (IND) , meaning it has not yet been approved by regulatory authorities
Key Points Binge eating disorder is one of the most common eating disorders in the United States
It is not a method of stabilizing hormones, and it does not replace the need to preserve lean mass during weight loss
Development of GLP-1GIPLani We previously showed that covalent attachment of the PPAR/ co-agonist Tesa to a pharmacokinetically optimized GLP-1R agonist enabled targeted delivery of Tesa into GLP-1R-expressing cells, leading to greater weight loss and further improvement of glucose control relative to treatment with pharmacokinetically-matched GLP-1R agonist backbone 26 (Extended Data Fig
Many patients starting GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) wonder about this potential side effect
Set Point Medical Weight Loss Clinic offers a comprehensive approach to weight management , providing personalized care tailored to each patients unique needs